STAT3 and neoplasm: Biomarkers that may guide treatment decisions include the tumor cell‐intrinsic expression of a functional IL‐6 receptor and the constitutive phosphorylation of the downstream transcription factor STAT3, which can be assessed by routine flow cytometric or immunohistochemical testing.